Michaela Mattheus - Concepedia

Author

Michaela Mattheus

Boehringer Ingelheim (Germany)ORCID

Also Known As

M Mattheus, M. Mattheus, MICHAELA MATTHEUS, Mark A. Espeland, Mattheus, Michaela, Matthew Weir, Michaela Mattheus

143

Publications

19.4K

Citations

H-Index

Concepts

All Affiliations

Boehringer Ingelheim (Germany)University of Toronto Lunenfeld-Tanenbaum Research Institute Yale University Mount Sinai Hospital

About

Michaela Mattheus is an author at Boehringer Ingelheim (Germany) specializing in medicine, pharmacology, and pharmacotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	11	12	869
2	Diabetes	8	8	762
3	Public Health	2	2	83
4	Epidemiology	2	2	83
5	Health Sciences	1	1	93

Michaela Mattheus

Publications

19.2K

Citations

H-Index

Page 1

	Year	Citations
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes Bernard Zinman, Christoph Wanner, John M. Lachin, New England Journal of Medicine	2015	11.6K
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes Christoph Wanner, Silvio E. Inzucchi, John M. Lachin, New England Journal of Medicine	2016	3.5K
Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes Julio Rosenstock, Steven E. Kahn, Odd Erik Johansen, JAMA	2019	578
Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease Christoph Wanner, John M. Lachin, Silvio E. Inzucchi, Circulation	2017	462
Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial David Z.I. Cherney, Bernard Zinman, Silvio E. Inzucchi, The Lancet Diabetes & Endocrinology Metabolic SyndromeDiabetes ManagementUrologyRenal FunctionCardiovascular Disease	2017	363
Empagliflozin after Acute Myocardial Infarction Javed Butler, W. Schuyler Jones, Jacob A. Udell, New England Journal of Medicine	2024	223
Design and baseline characteristics of the CARdiovascular Outcome Trial of LINAgliptin Versus Glimepiride in Type 2 Diabetes (CAROLINA<sup>®</sup>) Nikolaus Marx, Julio Rosenstock, Steven E. Kahn, Diabetes and Vascular Disease Research	2015	204
Characterization and implications of the initial estimated glomerular filtration rate ‘dip’ upon sodium-glucose cotransporter-2 inhibition with empagliflozin in the EMPA-REG OUTCOME trial Bettina J. Kraus, Matthew R. Weir, George L. Bakris, Kidney International	2020	197
Empagliflozin and Kidney Function Decline in Patients with Type 2 Diabetes: A Slope Analysis from the EMPA-REG OUTCOME Trial Christoph Wanner, Hiddo J.L. Heerspink, Bernard Zinman, Journal of the American Society of Nephrology	2018	194
Empagliflozin and Cerebrovascular Events in Patients With Type 2 Diabetes Mellitus at High Cardiovascular Risk Bernard Zinman, Silvio E. Inzucchi, John M. Lachin, Stroke	2017	133

Page 1